Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
XPO Appoints Michael Kneeland to Board of Directors
-
Expand Energy Corporation to Acquire Twin Eagle, Creating North America’s Leading Integrated Natural Gas Company
-
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
-
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
-
PPHC to Report Second Quarter 2026 Financial Results and Present at Upcoming Investor Conference
-
Troilus Selected by the Government of Quebec to Receive Specialized Support Through the New Filon Initiative for Strategic Mining Projects
-
Dmitry Shubov Consulting Issues Strategic Analysis on Capital-Efficient Delaware Flip Models for Southeast Asian Scale-Ups
-
Legence Sets Second Quarter 2026 Earnings Release Date and Webcast Schedule
-
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
-
Vanguard Food Announces Corporate Rebrand to Verdexa Holdings
-
Baker Hughes Secures Major LNG Technology Order for Venture Global’s CP2 LNG Expansion
-
Marex Group Limited to announce second quarter 2026 results on August 12, 2026
-
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
-
Fury Resumes Activities at Eau Claire
-
YieldMax® ETFs Announces Distributions on MSST, NVIT, and TEST
-
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
-
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
-
Novo Nordisk A/S - share repurchase programme
-
Dimensional Fund Advisors Ltd. : Form 8.3 - PROLOGIS INC - Ordinary Shares
-
W&T Offshore Announces Timing of Second Quarter 2026 Earnings Release and Conference Call
-
SPX Announces Appointment of New Board Member
-
Vireo Growth Inc. to Acquire Planet 13 Holdings Inc.
-
Dimensional Fund Advisors Ltd. : Form 8.3 - GAMMA COMMUNICATIONS PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - DCC Energy PLC - Ordinary Shares
-
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
-
Heineken Holding N.V. reports transactions under its current share buyback programme
-
Heineken N.V. reports the progress of transactions under its current share buyback programme
-
CorVel Corporation to Host Live Earnings Release Webcast
-
iLands launches: A Shared Economic Network Where Autonomous AI Agents and Humans Work, Trade, and Co-evolve
-
Transactions in connection with share buyback programme
-
HKTB's Hong Kong Summer Fun Adds Ticket Spending Offers
-
HKTB's Hong Kong Summer Fun Adds Ticket Spending Offers
-
The Ensign Group Reports Second Quarter 2026 Results
-
Total Voting Rights and Transaction in Own Shares
-
Allot to Release Second Quarter 2026 Results and Host Conference Call on August 12, 2026
-
Asante Gold Announces Management Change
-
Rocket Lab Awarded Record $266M Missile Defense Contract with U.S. Space Force for Suborbital Launches
-
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
-
Legend Biotech Announces CEO Transition
-
KBR Selected by Power2X as Project Management Consultant for its eFuels Project in Rotterdam
-
Artel Announces New Carrier-Class PTP Switch Built for the Demands of Modern Broadcast
-
Nokia Corporation - Managers' transactions (Mahajan)
-
Nokia Corporation - Managers' transactions (Ihamuotila)
-
Nokia Corporation - Managers' transactions (Hammarén)
-
Man Group PLC : Form 8.3 - AMG Critical Materials N.V
-
Man Group PLC : Form 8.3 - Gamma Communications Plc
-
Man Group PLC : Form 8.3 - Senior plc
-
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
-
Toobit Launches Exclusive Welcome Package for New Traders
-
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
